Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides. - Wikidata - awgldk - TriplyDB

Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides.

Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides.

http://www.wikidata.org/entity/Q35070501

about

Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals Vitamin D and chronic hepatitis C: effects on success rate and prevention of side effects associated with pegylated interferon-α and ribavirin Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories Targeting host lipid synthesis and metabolism to inhibit dengue and hepatitis C viruses.Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection.Quantitative Analysis of Hepatitis C NS5A Viral Protein Dynamics on the ER Surface.Hijacking of multiple phospholipid biosynthetic pathways and induction of membrane biogenesis by a picornaviral 3CD protein.

P2860

Q26746563-A2EA8EDB-E46A-4865-A2C3-D39E315321DD Q26773321-B0B23A8E-C78A-4056-B382-A1BE0F0E5726 Q26784321-0AEF297E-DD89-4A16-A23C-A85EFC19EA6F Q35385005-B0094517-775B-46A3-B0E4-0E50A083783C Q36425870-F42A20FE-3C65-4BDE-BE39-6316002756E1 Q38612647-874EDCB8-4A3F-4367-A5C6-ADF10B2DC292 Q47216796-2CD6D04B-A2E9-472E-BF08-DA4E45F86763 Q54978666-CBA7EFE4-E70D-4F9F-B758-DE44F47D81F6

P2860

Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides.

http://www.wikidata.org/entity/Q35070501

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Daclatasvir inhibits hepatitis ...... mulation of phosphoinositides.

@ast

Daclatasvir inhibits hepatitis ...... mulation of phosphoinositides.

@en

type

label

Daclatasvir inhibits hepatitis ...... mulation of phosphoinositides.

@ast

Daclatasvir inhibits hepatitis ...... mulation of phosphoinositides.

@en

prefLabel

Daclatasvir inhibits hepatitis ...... mulation of phosphoinositides.

@ast

Daclatasvir inhibits hepatitis ...... mulation of phosphoinositides.

@en

P1433

Q35070501-D89C30E4-0887-42AB-B7C0-7E17C6F5167E

P1476

Q35070501-062D6ED0-4AF9-46CB-9A2D-41D51C3A237D

P2093

Q35070501-48B0B571-7968-47BF-A764-BC17F0A65132

Q35070501-955BA601-AEE0-4E88-AE9F-18D48FB11AD8

Q35070501-B04B879F-ED55-4490-AEC2-B719172F0DF3

Q35070501-ED0F5BDC-3362-4254-BC62-225BD244A03D

P2860

Q35070501-01472688-DEB0-4B83-9A1E-A192FDF27F21

Q35070501-063FED78-4BF3-4BFA-99E6-A8A2AA72F1EA

Q35070501-06CF4B3A-89F0-489B-A6E2-9083CE4964F2

Q35070501-0D853F82-D962-41FE-A90C-A04904058F6F

Q35070501-19F1E632-F66C-4C49-BD89-952F394899A9

Q35070501-1E7E88DB-23C2-4329-BE9C-97ECCA470906

Q35070501-2C61D967-47E5-435C-A528-40F8846188D6

Q35070501-2D287AA1-19AB-4D61-8C47-B1E23DCF7F20

Q35070501-303E3F28-9E81-4DB2-A43A-B5D7EC46D58F

Q35070501-3454AC6F-684F-42E2-B549-E719134E9B90

P304

Q35070501-D664255E-B1E9-4D90-86B2-83C61A7BB8A1

P31

Q35070501-CE47A0B7-DBD3-461B-B7E3-65E7AC4F41E5

P356

Q35070501-94859D14-03BF-44DA-933C-C191D2381DCC

P407

Q35070501-EE15FD8C-EC79-4604-8BB5-574502E38CF1

P478

Q35070501-BBB0028E-0134-4854-9556-3F56DA9DC780

P50

Q35070501-39CE669B-A9D1-4BE6-8CFA-954A545D5DBE

Q35070501-7A341176-E6D2-4406-B70B-2AB70467A3CF

P577

Q35070501-27D56E61-94DA-4ECA-A930-4C7188197C13

P698

Q35070501-72242CDC-EAA8-4199-9400-7E565231C7C4

P932

Q35070501-EFD6E047-2D83-4355-BF49-C637CA3AAEAF

P356

J.VIROL.2014.12.018

P1433

P1476

Daclatasvir inhibits hepatitis ...... mulation of phosphoinositides.

@en

P2093

Kristi L Berger

http://www.w3.org/2001/XMLSchema#string

Meryl Thomas

http://www.w3.org/2001/XMLSchema#string

Sean M Kelly

http://www.w3.org/2001/XMLSchema#string

Vineela Chukkapalli

http://www.w3.org/2001/XMLSchema#string

P2860

The lipid kinase phosphatidylinositol-4 kinase III alpha regulates the phosphorylation status of hepatitis C virus NS5A

Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment

Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication

Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential

Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase

Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras

Viral and Cellular Determinants of Hepatitis C Virus RNA Replication in Cell Culture

Identification of the Hepatitis C Virus RNA Replication Complex in Huh-7 Cells Harboring Subgenomic Replicons

Essential Role of Domain III of Nonstructural Protein 5A for Hepatitis C Virus Infectious Particle Assembly

Intragenotypic JFH1 based recombinant hepatitis C virus produces high levels of infectious particles but causes increased cell death

P304

168-179

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VIROL.2014.12.018

http://www.w3.org/2001/XMLSchema#string

P407

P478

476

http://www.w3.org/2001/XMLSchema#string

P50

Alexander Deiters

P577

2014-12-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25546252

http://www.w3.org/2001/XMLSchema#string

P932

4323755

http://www.w3.org/2001/XMLSchema#string